Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro

Table 2 Sizing, zeta-potential and antifungal activity of drug, cationic lipid, and polyelectrolyte(s) assemblies

Cationic lipid, drug and polyelectrolyte assemblies	D ± δ (nm)	ζ ± δ (mV)	Viability (%)
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PDDA(1)	171 ± 1	24 ± 2	79 ± 5
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL_5000–10000 (1)	92 ± 4	40 ± 1	71 ± 4
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL_{30000–70000} (1)	138 ± 5	50 ± 3	21 ± 9
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL_{70000–150000} (1)	148 ± 5	60 ± 3	13 ± 5
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PDDA (1)	280 ± 2	35 ± 1	27 ± 2
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL_5000–10000 (1)	238 ± 1	25 ± 7	37 ± 1
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL_{30000–70000} (1)	326 ± 5	36 ± 3	23 ± 6
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL_{70000–150000} (1)	417 ± 3	47 ± 5	11 ± 3

Zeta-average diameter (D) and zeta-potential (ζ) of novel cationic AmB formulations and their effect on C. albicans viability at low and high drug-to-lipid molar proportions. Concentrations are given within parentheses in mg/mL. One should notice that polylysine (PL) with diferent molecular weights may alternatively replace PDDA and be used to control the positive zeta-potential of the outer layer.

ISSN: 1477-3155